A166480 Stock Overview
A bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
CORESTEMCHEMON Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,365.00 |
| 52 Week High | ₩15,610.00 |
| 52 Week Low | ₩2,765.00 |
| Beta | 1.04 |
| 1 Month Change | -3.86% |
| 3 Month Change | -10.51% |
| 1 Year Change | -68.37% |
| 3 Year Change | -73.71% |
| 5 Year Change | -79.97% |
| Change since IPO | -91.91% |
Recent News & Updates
CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Price Is Right But Growth Is Lacking
Apr 14
Is CORESTEMCHEMON (KOSDAQ:166480) Using Too Much Debt?
Feb 20CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Popularity With Investors Under Threat As Stock Sinks 25%
Dec 09Recent updates
CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Price Is Right But Growth Is Lacking
Apr 14Is CORESTEMCHEMON (KOSDAQ:166480) Using Too Much Debt?
Feb 20CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Popularity With Investors Under Threat As Stock Sinks 25%
Dec 09Is CORESTEMCHEMON (KOSDAQ:166480) A Risky Investment?
Nov 01CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 27% Price Boost Is Out Of Tune With Revenues
Sep 24Would CORESTEMCHEMON (KOSDAQ:166480) Be Better Off With Less Debt?
Aug 03What CORESTEMCHEMON Inc.'s (KOSDAQ:166480) 26% Share Price Gain Is Not Telling You
Jun 08CORESTEMCHEMON Inc.'s (KOSDAQ:166480) Shares Bounce 25% But Its Business Still Trails The Industry
Mar 05Does CORESTEM (KOSDAQ:166480) Have A Healthy Balance Sheet?
Apr 12If You Had Bought CORESTEM (KOSDAQ:166480) Shares A Year Ago You'd Have Earned 59% Returns
Feb 16Corestem (KOSDAQ:166480) Has Debt But No Earnings; Should You Worry?
Dec 25Shareholder Returns
| A166480 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -6.0% | -2.3% | 0.6% |
| 1Y | -68.4% | 13.4% | -7.9% |
Return vs Industry: A166480 underperformed the KR Biotechs industry which returned 13.4% over the past year.
Return vs Market: A166480 underperformed the KR Market which returned -7.9% over the past year.
Price Volatility
| A166480 volatility | |
|---|---|
| A166480 Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in KR Market | 12.2% |
| 10% least volatile stocks in KR Market | 2.9% |
Stable Share Price: A166480's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A166480's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Kyung-Suk Kim | www.corestem.com |
CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases.
CORESTEMCHEMON Inc. Fundamentals Summary
| A166480 fundamental statistics | |
|---|---|
| Market cap | ₩81.97b |
| Earnings (TTM) | -₩26.25b |
| Revenue (TTM) | ₩28.76b |
2.8x
P/S Ratio-3.1x
P/E RatioIs A166480 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A166480 income statement (TTM) | |
|---|---|
| Revenue | ₩28.76b |
| Cost of Revenue | ₩29.97b |
| Gross Profit | -₩1.21b |
| Other Expenses | ₩25.05b |
| Earnings | -₩26.25b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08k |
| Gross Margin | -4.20% |
| Net Profit Margin | -91.27% |
| Debt/Equity Ratio | 94.5% |
How did A166480 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 07:18 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CORESTEMCHEMON Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Byung Hwa Han | Eugene Investment & Securities Co Ltd. |
| Jiyong Lee | Shinhan Investment Corp. |
| Choongwoo Seo | SK Securities Co., Ltd. |